| [1] |
王冲，王贵松，李月红. 异常高密度脂蛋白在慢性肾脏病中的研究进展[J]. 中华肾脏病杂志，2019, 35(4): 316-320.
|
| [2] |
Haynes R, Lewis D, Emberson J, et al. Effects of lowering LDL cholesterol on progression of kidney disease [J]. J Am Soc Nephrol, 2014, 25(8): 1825-1833.
|
| [3] |
彭熙，李晓华，马云华，等. 不同类型血脂异常对IgA肾病临床及病理特征的影响[J/CD]. 中华肾病研究电子杂志，2016, 5(5): 214-217.
|
| [4] |
Wanner C, Tonelli M. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient [J]. Kidney Int, 2014, 85(6): 1303-1309.
|
| [5] |
Mathew RO, Rosenson RS, Lyubarova R, et al. Concepts and controversies: lipid management in patients with chronic kidney disease [J]. Cardiovasc Drugs Ther, 2021, 35(3): 479-489.
|
| [6] |
Rahman M, Yang W, Akkina S, et al. Relation of serum lipids and lipoproteins with progression of CKD: the CRIC study [J]. Clin J Am Soc Nephrol, 2014, 9(7): 1190-1198.
|
| [7] |
Tsai C, Huang H, Chiang H, et al. Longitudinal lipid trends and adverse outcomes in patients with CKD: a 13-year observational cohort study [J]. J Lipid Res, 2019, 60(3): 648-660.
|
| [8] |
Toth PP, Dwyer JP, Cannon CP, et al. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease [J]. Kidney Int, 2018, 93(6): 1397-1408.
|
| [9] |
Catapano AL, Graham I, De Backer G, et al. 2016 ESC/EAS guidelines for the management of dyslipidaemias [J]. Eur Heart J, 2016, 37(39): 2999-3058.
|
| [10] |
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk [J]. Eur Heart J, 2020, 41(1): 111-188.
|
| [11] |
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines [J]. J Am Coll Cardiol, 2014, 63(25 Pt B): 2889-2934.
|
| [12] |
Grundy S, Stone N, Bailey A, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines [J]. Circulation, 2019, 139(25): e1082-e1143.
|
| [13] |
Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: executive summary: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines [J]. J Am Coll Cardiol, 2019, 74(10): 1376-1414.
|
| [14] |
Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk [J]. Eur Heart J, 2020, 41(1): 111-188.
|
| [15] |
Jacobson TA, Ito MK, Maki KC, et al. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1—full report [J]. J Clin Lipidol, 2015, 9(2): 129-169.
|
| [16] |
Mach F, Ray KK, Wiklund O, et al. Adverse effects of statin therapy: perception vs. the evidence - focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract [J]. Eur Heart J, 2018, 39(27): 2526-2539.
|
| [17] |
杨文领，张现化，闵青，等. 辛伐他汀在终末期肾病患者中的群体药代动力学研究[J]. 中华肾脏病杂志，2013, 29(4): 302-303.
|
| [18] |
Streja E, Streja DA, Soohoo M, et al. Precision medicine and personalized management of lipoprotein and lipid disorders in chronic and end-stage kidney disease [J]. Semin Nephrol, 2018, 38(4): 369-382.
|
| [19] |
Tunon J, Steg PG, Bhatt DL, et al. Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial [J]. Eur Heart J, 2020, 41(42): 4114-4123.
|
| [20] |
Toth PP, Dwyer JP, Cannon CP, et al. Efficacy and safety of lipid lowering by alirocumab in chronic kidney disease [J]. Kidney Int, 2018, 93(6): 1397-1408.
|
| [21] |
Charytan DM, Sabatine MS, Pedersen TR, et al. Efficacy and safety of evolocumab in chronic kidney disease in the FOURIER trial [J]. J Am Coll Cardiol, 2019, 73(23): 2961-2970.
|
| [22] |
Boer IH, Zelnick LR, Ruzinski J, et al. Effect of vitamin D and omega-3 fatty acid supplementation on kidney function in patients with type 2 diabetes: a randomized clinical trial [J]. JAMA, 2019, 322(19): 1899-1909.
|
| [23] |
Palmer SC, Navaneethan SD, Craig JC, et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis [DB/OL]. Cochrane Database Syst Rev, 2014, 5: CD007784.
|
| [24] |
Rivera M, Tamariz L, Suarez M, et al. Modifying effect of statins on fatal outcomes in chronic kidney disease patients in the systolic blood pressure intervention trial: a post hoc analysis [J]. Am J Nephrol, 2019, 49(4): 297-306.
|
| [25] |
Su X, Zhang L, Lv J, et al. Effect of statins on kidney disease outcomes: a systematic review and meta-analysis [J]. Am J Kidney Dis, 2016, 67(6): 881-892.
|
| [26] |
Sandhu S, Wiebe N, Fried LF, et al. Statins for improving renal outcomes: a meta-analysis [J]. J Am Soc Nephrol, 2006, 17(7): 2006-2016.
|
| [27] |
Palmer SC, Navaneethan SD, Craig JC, et al. HMG CoA reductase inhibitors (statins) for dialysis patients [DB/OL]. Cochrane Database Syst Rev, 2013, 9: CD004289.
|
| [28] |
Ferro CJ, Mark PB, Kanbay M, et al. Lipid management in patients with chronic kidney disease [J]. Nat Rev Nephrol, 2018, 14(12): 727-749.
|
| [29] |
Chung CM, Lin MS, Chang CH, et al. Moderate to high intensity statin in dialysis patients after acute myocardial infarction: a national cohort study in Asia [J]. Atherosclerosis, 2017, 267: 158-166.
|
| [30] |
Ota Y, Kitamura M, Muta K, et al. Effect of statin on life prognosis in Japanese patients undergoing hemodialysis [J]. PLoS One, 2019, 14(10): e0224111.
|
| [31] |
Krane V, Schmidt KR, Gutjahr-Lengsfeld LJ, et al. Long-term effects following 4 years of randomized treatment with atorvastatin in patients with type 2？diabetes mellitus on hemodialysis [J]. Kidney Int, 2016, 89(6): 1380-1387.
|
| [32] |
Park CH, Kang EW, Park JT, et al. Association of serum lipid levels over time with survival in incident peritoneal dialysis patients [J]. J Clin Lipidol, 2017, 11(4): 945-954.
|
| [33] |
Genser B, Wanner C, März W. A scoring system for predicting individual treatment effects of statins in type 2 diabetes patients on haemodialysis [J]. Eur J Prev Cardiol, 2021, 28(8): 838-851.
|
| [34] |
Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA study): a prospective randomised controlled trial [J]. Lancet, 2006, 368(9542): 1155-1163.
|
| [35] |
Shen H, Chen X, Lu J, et al. Effects of statin therapy on chronic kidney disease patients with coronary artery disease [J]. Lipids Health Dis, 2018, 17(1): 84.
|
| [36] |
Singh M, Mcevoy JW, Khan SU, et al. Comparison of transatlantic approaches to lipid management: the AHA/ACC/multisociety guidelines vs the ESC/EAS guidelines [J]. Mayo Clin Proc, 2020, 95(5): 998-1014.
|
| [37] |
de Zeeuw D, Anzalone DA, Cain VA, et al. Renal effects of atorvastatin and rosuvastatin in patients with diabetes who have progressive renal disease (PLANET I): a randomised clinical trial [J]. Lancet Diabetes Endocrinol, 2015, 3(3): 181-190.
|
| [38] |
Idzerda MA, Pena MJ, Parving HH, et al. Proteinuria and cholesterol reduction are independently associated with less renal function decline in statin-treated patients; a post hoc analysis of the PLANET trials [J]. Nephrol Dial Transplant, 2019, 34(10): 1699-1706.
|
| [39] |
Fiedler R, Jehle PM, Osten B, et al. Clinical nutrition scores are superior for the prognosis of haemodialysis patients compared to lab markers and bioelectrical impedance [J]. Nephrol Dial Transplant, 2009, 24(12): 3812-3817.
|